We explore the complex interplay between tumor-intrinsic drivers of resistance, such as mutations in key genes like PBRM1, and the profoundly immunosuppressive landscape of the tumor microenvironment (TME), which includes diverse inhibitory cell populations, metabolic reprogramming, and stromal barriers. Here, PBRM1 is linked to neoplasm.